To identify the patients with higher response rates, researchers have proposed several predictive biomarkers such as PD-L1 expression levels (Hui et al., 2017) and tumor mutation burden (TMB) (Osipov et al., 2020). The gene discussed is CD274; the disease is neoplasm.